Voya Investment Management LLC Cuts Position in uniQure (NASDAQ:QURE)

Voya Investment Management LLC lowered its holdings in uniQure (NASDAQ:QURE - Free Report) by 58.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 49,055 shares of the biotechnology company's stock after selling 68,970 shares during the quarter. Voya Investment Management LLC owned 0.10% of uniQure worth $866,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock valued at $195,000 after purchasing an additional 969 shares during the period. Wells Fargo & Company MN increased its holdings in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after buying an additional 1,503 shares in the last quarter. Twin Tree Management LP purchased a new stake in shares of uniQure during the 4th quarter worth approximately $77,000. FNY Investment Advisers LLC purchased a new stake in shares of uniQure during the 4th quarter worth approximately $88,000. Finally, Geode Capital Management LLC grew its holdings in shares of uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company's stock worth $2,509,000 after acquiring an additional 6,362 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Price Performance

QURE stock opened at $10.07 on Thursday. The stock has a market capitalization of $551.81 million, a price-to-earnings ratio of -2.03 and a beta of 0.10. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The stock's fifty day simple moving average is $12.16 and its 200-day simple moving average is $11.97.

Wall Street Analysts Forecast Growth

QURE has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $70.00 target price on shares of uniQure in a research report on Monday, April 21st. StockNews.com raised shares of uniQure to a "sell" rating in a research note on Tuesday, March 11th. Wells Fargo & Company reduced their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Chardan Capital reissued a "buy" rating and set a $38.00 price objective on shares of uniQure in a research note on Tuesday. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, uniQure currently has an average rating of "Moderate Buy" and a consensus target price of $38.80.

Insiders Place Their Bets

In other news, CFO Christian Klemt sold 14,341 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now directly owns 152,372 shares in the company, valued at $1,630,380.40. This represents a 8.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 28,341 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares of the company's stock, valued at approximately $6,703,461.66. The trade was a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 90,830 shares of company stock valued at $961,401. Insiders own 4.74% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.